Page last updated: 2024-09-03

gefitinib and Eye Disorders

gefitinib has been researched along with Eye Disorders in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Basti, S; Borkar, DS; Lacouture, ME	1
Bristow, E; Esmaeli, B; Faulkner, K; Forsythe, BJ; Murray, PI; Tullo, AB	1

Trials

1 trial(s) available for gefitinib and Eye Disorders

Article	Year
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (London, England), 2005, Volume: 19, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders	2005

Article

Year

Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.

Eye (London, England), 2005, Volume: 19, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders

2005

Other Studies

1 other study(ies) available for gefitinib and Eye Disorders

Article	Year
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies	2013

Article

Year

Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:4

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies

2013